Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials

AUTOR(ES)

Bloom, Romi, Amber, Kyle T.

FONTE

An. Bras. Dermatol.

DATA DE PUBLICAÇÃO

2017-02

RESUMO

ABSTRACT Lamotrigine is an antiepileptic drug used for the treatment of epilepsy, bipolar disorder and numerous off-label uses. The development of rash significantly affects its use. The most concerning of these adverse reactions is Stevens-Johnson syndrome/toxic epidermal necrolysis. We performed a systematic review of randomized controlled trials using lamotrigine as a monotherapy to quantify the incidence of cutaneous reactions, particularly Stevens-Johnson syndrome/toxic epidermal necrolysis. Of a total of 4,364 papers regarding lamotrigine, 122 studies met our inclusion and exclusion criteria. In total, 18,698 patients were included with 1,570 (8.3%) of patients experiencing an adverse dermatologic reaction. The incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis was 0.04%.

Documentos Relacionados

• Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals
• Ectopic conjunctivalisation in Stevens-Johnson syndrome.
• Evaluation of conjunctival bacterial flora in patients with Stevens-Johnson Syndrome
• Mycoplasma pneumonia, Stevens-Johnson syndrome, and chronic obliterative bronchitis.
• Toll‐like receptor 3 gene polymorphisms in Japanese patients with Stevens–Johnson syndrome